The two year, $600,000 grant will be used to identify novel highly protective antigens for malaria vaccine development.
The work under this grant will build on the research that was started under a Small Business Innovation and Research grant from the NIAID in 2009.
GenVec will partner with the US Naval Medical Research Center (NMRC) to apply its adenovector technology to the development of malaria vaccine candidates.
GenVec malaria program head and research director Joseph Bruder said the grant will further the company’s efforts in identifying novel antigens for malaria vaccine development.